The European Society for Medical Oncology (ESMO) is calling on European politicians to voice their support for a decisive step to help ensure cancer patients receive the best possible treatment.
At a meeting of the European Commission today representatives from all EU Member States met in Brussels to consider the status of medical oncology as a recognized specialty under EU law.
“Such recognition is an essential step in providing optimal treatment to the millions of Europeans who have cancer or who develop cancer every year,” says Dr. Jose Baselga, ESMO President-Elect. It would enable the free movement of medical oncologists within EU Member States, with their professional qualifications being automatically recognized.
“A determining factor for optimal cancer treatment and research is the level of training, knowledge and skills of oncology professionals,” says Dr. Baselga.
Medical oncologists are doctors who specialize in taking care of cancer patients. They have training in internal medicine, and subsequent specialization in the comprehensive management of patients with malignancies.
Medical oncologists are trained in the scientific basis of cancer treatment, prevention, screening, and diagnosis. Hospitals in every European country, and around the world, employ medical oncologists to help treat their patients.
“Medical oncology is recognized as a specialty in most of the EU Member States, the United States and many other countries around the world,” says Dr. Adamos Adamou, co-chair of the European Members of Parliament Against Cancer (MAC). “We believe it is time the EU joined them.”
Working in multidisciplinary teams with surgeons and radiation oncologists, medical oncologists are responsible for the systemic treatment of cancer patients with chemotherapy, hormonal therapy, immune and targeted therapies, as well as supportive care. Medical oncologists also engage in clinical cancer research in the form of clinical trials.
Currently, however, the specialty of medical oncology is not formally recognized by the European Union. Discussions within the EU have been ongoing for some time in a continuing and concerted effort on the part of medical professionals from across the continent to achieve that recognition.
“We urge patients and politicians to voice their support for the recognition of medical oncology as a specialty, and to agree on minimum training periods,” says Pascale Blaes, Director of the ESMO Brussels office.
“Oncologists and cancer patients across the EU will be watching the outcome closely, because of the growing urgency to keep cancer as a high priority on the EU healthcare agenda,” Pascale Blaes says.
About ESMO: The European Society for Medical Oncology (ESMO) is the leading European non-profit, professional organization for medical oncology promoting multidisciplinary cancer treatment around the world. ESMO unites medical oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers, the media and other key stakeholders in a global alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Thanks to its state-of-the-art education and training programs, ESMO plays an instrumental role in providing the oncology community with the most up-to-date scientific research and information available. Annals of Oncology, ESMO’s flagship journal, ranks among the top five clinical oncology journals worldwide. ESMO is dedicated to educating and supporting oncologists, optimizing patient care, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative voice in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations, as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment.
For more information about ESMO, please visit www.esmo.org